Product Code: PHA1338
The global Decentralised Clinical Trials market is estimated to grow at a CAGR of 7.6% by 2034
The Decentralised Clinical Trials Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Globalisation of Clinical Trials
The globalization of clinical trials is fundamentally transforming the clinical trials market. The underline growth is driven by the expanding clinical trials that indicate towards a significant shift in the healthcare landscape. There is a growing need to accelerate drug development timelines, reduce costs, and access of innovative drugs to the diverse patient populations. The pharmaceutical and biotech companies invest heavily into conducting clinical trials to gather comprehensive clinical data across different countries. Gathering clinical data from diverse populations has a profound impact on the development and efficacy of medical treatments. By including participants from various ethnic, genetic, and socio-economic backgrounds, clinical trials can produce more comprehensive and generalizable data. This diversity helps in understanding how different groups respond to treatments, which can uncover variations in drug efficacy and potential side effects that might not be apparent in a homogenous study group.
Globalization is essential in promoting regulatory harmonization across various regions, offering substantial advantages to the clinical trials market. By standardizing regulatory guidelines and procedures internationally, pharmaceutical companies can more easily manage the intricate approval processes in multiple countries at once. This alignment minimizes redundant efforts and simplifies the development and authorization of new therapies. As a result, the time-to-market for cutting-edge treatments is reduced, allowing patients globally to access new medical innovations more quickly. Furthermore, a cohesive regulatory framework fosters increased collaboration and data exchange among researchers worldwide, improving the overall quality and effectiveness of clinical trials.
Concerns Related to Safety and Privacy of Clinical Trials Data
Digital clinical trials (DCTs) heavily rely on digital health technologies and remote data collection methods, making the protection of sensitive patient information a top priority. Concerns regarding data privacy and security can emerge from multiple sources, including unauthorized access to personal health data, breaches of electronic systems, and non-adherence to data protection regulations. Remote monitoring devices, mobile applications, and telemedicine platforms may gather a plethora of sensitive health information, spanning medical history, treatment details, and biometric data. Unauthorized access or misuse of this data could result in privacy breaches, identity theft, and reputational harm for both patients and research organizations.
Data transmission may occur across various platforms, devices, and geographical locations, heightening the risk of data exposure or interception during transit. Moreover, involving third-party vendors like technology providers and cloud service providers further complicates the data security landscape, as these entities may have access to sensitive patient information. Clinical trials often span multiple countries with differing legal jurisdictions, posing challenges in comprehending and adhering to data privacy requirements. Variations in local interpretations of privacy laws in relation to clinical trials contribute to this complexity.
What Questions Should You Ask before Buying a Market Research Report?
How is the decentralised clinical trials Market evolving?
What is driving and restraining the decentralised clinical trials market?
How will each decentralised clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
How will the market shares for each decentralised clinical trials submarket develop from 2024 to 2034?
What will be the main driver for the overall market from 2024 to 2034?
Will leading decentralised clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
Who are the leading players and what are their prospects over the forecast period?
What are the decentralised clinical trials projects for these leading companies?
How will the industry evolve during the period between 2024 and 2034? What are the implications of decentralised clinical trials projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the decentralised clinical trials market?
Where is the decentralised clinical trials market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Decentralised Clinical Trials Market today, and over the next 10 years:
Our 321-page report provides 141 tables and 168 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Decentralised Clinical Trials Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Decentralised Clinical Trials prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report
Study Design
Interventional
Observational
Expanded access
Indication
Oncology
Cardiovascular
Immunology
Respiratory
Others
Component
Mobile Healthcare
Telemedicine
Wearable Devices
Web-based Technology
Others
End-users
Pharmaceutical and Biopharmaceutical Companies
CROs
Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 27 leading national markets:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Poland
Belgium
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Singapore
Taiwan
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of Latin America
MEA
GCC
South Africa
Rest of MEA
The report also includes profiles and for some of the leading companies in the Decentralised Clinical Trials Market, 2024 to 2034, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
Castor
Clario
Clinical Ink
Cloudbyz
Dassault SystemesSE (Medidata Solutions, Inc.)
Ergomed Group
Florence Healthcare, Inc.
ICON Plc
IQVIA Inc.
KORE Wireless Group, Inc.
Laboratory Corporation of America Holdings (Covance)
Medable Inc.
Medrio
Oracle Life Sciences
Parexel International (MA) Corporation
ProPharma Group MIS Limited
Science 37
Signant Health (CRF Bracket)
Syneos Health
Thermo Fisher Scientific Inc. (PPD)
Veeva Systems
Overall world revenue for Decentralised Clinical Trials Market, 2024 to 2034 in terms of value the market will surpass US$9,200.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Decentralised Clinical Trials Market, 2024 to 2034 report help you?
In summary, our 320+ page report provides you with the following knowledge:
Revenue forecasts to 2034 for Decentralised Clinical Trials Market, 2024 to 2034, with forecasts for study design, indication, end-users and component, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2034 for five regional and 27 key national markets - See forecasts for the Decentralised Clinical Trials Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 20 of the major companies involved in the Decentralised Clinical Trials Market, 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Decentralised Clinical Trials Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Decentralised Clinical Trials Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report
- 1.6 Who is This Report for?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Advancements in Digital Health Technologies
- 3.2.1.2 Globalisation of Clinical Trials
- 3.2.1.3 Increasing Demand for Real-World Evidence
- 3.2.1.4 Regulatory Support and Guidance
- 3.2.2 Market Restraining Factors
- 3.2.2.1 Data Privacy and Security Concerns
- 3.2.2.2 Technological Limitations and Standardization
- 3.2.2.3 Infrastructure and Resource Constraints
- 3.2.3 Market Opportunities
- 3.2.3.1 Acceleration of Drug Development and Innovation
- 3.2.3.2 Expansion of Clinical Trial Activities into Emerging Markets
- 3.2.3.3 Increasing Partnerships and Collaborations Between Pharmaceutical Companies
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
- 3.4.1 Bargaining Power of Suppliers
- 3.4.2 Bargaining Power of Buyers
- 3.4.3 Competitive Rivalry
- 3.4.4 Threat of Substitutes
- 3.4.5 Threat of New Entrants
- 3.5 PEST Analysis
4 Decentralised Clinical Trials Market Analysis by Study Design
- 4.1 Key Findings
- 4.2 Study Design Segment: Market Attractiveness Index
- 4.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
- 4.4 Interventional
- 4.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.4.2 Market Share by Region, 2024 & 2034 (%)
- 4.5 Observational
- 4.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.5.2 Market Share by Region, 2024 & 2034 (%)
- 4.6 Expanded Access
- 4.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 4.6.2 Market Share by Region, 2024 & 2034 (%)
5 Decentralised Clinical Trials Market Analysis by Indication
- 5.1 Key Findings
- 5.2 Study Design Segment: Market Attractiveness Index
- 5.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
- 5.4 Oncology
- 5.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.4.2 Market Share by Region, 2024 & 2034 (%)
- 5.5 Cardiovascular
- 5.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.5.2 Market Share by Region, 2024 & 2034 (%)
- 5.6 Immunology
- 5.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.6.2 Market Share by Region, 2024 & 2034 (%)
- 5.7 Respiratory
- 5.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.7.2 Market Share by Region, 2024 & 2034 (%)
- 5.8 Others
- 5.8.1 Market Size by Region, 2024-2034 (US$ Million)
- 5.8.2 Market Share by Region, 2024 & 2034 (%)
6 Decentralised Clinical Trials Market Analysis by End-users
- 6.1 Key Findings
- 6.2 End-user Segment: Market Attractiveness Index
- 6.3 Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
- 6.4 Pharmaceutical & Biopharmaceutical Companies
- 6.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.4.2 Market Share by Region, 2024 & 2034 (%)
- 6.5 Clinical Research Organisations (CROs)
- 6.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.5.2 Market Share by Region, 2024 & 2034 (%)
- 6.6 Others
- 6.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 6.6.2 Market Share by Region, 2024 & 2034 (%)
7 Decentralised Clinical Trials Market Analysis by Component
- 7.1 Key Findings
- 7.2 Component Segment: Market Attractiveness Index
- 7.3 Decentralised Clinical Trials Market Size Estimation and Forecast by Component
- 7.4 Mobile Healthcare
- 7.4.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.4.2 Market Share by Region, 2024 & 2034 (%)
- 7.5 Telemedicine
- 7.5.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.5.2 Market Share by Region, 2024 & 2034 (%)
- 7.6 Wearable Devices
- 7.6.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.6.2 Market Share by Region, 2024 & 2034 (%)
- 7.7 Web-based Technology
- 7.7.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.7.2 Market Share by Region, 2024 & 2034 (%)
- 7.8 Others
- 7.8.1 Market Size by Region, 2024-2034 (US$ Million)
- 7.8.2 Market Share by Region, 2024 & 2034 (%)
8 Decentralised Clinical Trials Market Analysis by Region
- 8.1 Key Findings
- 8.2 Regional Market Size Estimation and Forecast
9 North America Decentralised Clinical Trials Market Analysis
- 9.1 Key Findings
- 9.2 North America Decentralised Clinical Trials Market Attractiveness Index
- 9.3 North America Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
- 9.4 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Country
- 9.5 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
- 9.6 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
- 9.7 North America Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
- 9.8 North America Decentralised Clinical Trials Market Size Estimation and Forecast by Component
- 9.9 U.S. Decentralised Clinical Trials Market Analysis
- 9.10 Canada Decentralised Clinical Trials Market Analysis
10 Europe Decentralised Clinical Trials Market Analysis
- 10.1 Key Findings
- 10.2 Europe Decentralised Clinical Trials Market Attractiveness Index
- 10.3 Europe Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
- 10.4 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Country
- 10.5 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
- 10.6 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
- 10.7 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
- 10.8 Europe Decentralised Clinical Trials Market Size Estimation and Forecast by Component
- 10.9 Germany Decentralised Clinical Trials Market Analysis
- 10.10 France Decentralised Clinical Trials Market Analysis
- 10.11 UK Decentralised Clinical Trials Market Analysis
- 10.12 Italy Decentralised Clinical Trials Market Analysis
- 10.13 Spain Decentralised Clinical Trials Market Analysis
- 10.14 Russia Decentralised Clinical Trials Market Analysis
- 10.15 Poland Decentralised Clinical Trials Market Analysis
- 10.16 Belgium Decentralised Clinical Trials Market Analysis
- 10.17 Rest of Europe Decentralised Clinical Trials Market Analysis
11 Asia Pacific Decentralised Clinical Trials Market Analysis
- 11.1 Key Findings
- 11.2 Asia Pacific Decentralised Clinical Trials Market Attractiveness Index
- 11.3 Asia Pacific Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
- 11.4 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Country
- 11.5 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
- 11.6 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
- 11.7 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
- 11.8 Asia Pacific Decentralised Clinical Trials Market Size Estimation and Forecast by Component
- 11.9 Japan Decentralised Clinical Trials Market Analysis
- 11.10 China Decentralised Clinical Trials Market Analysis
- 11.11 India Decentralised Clinical Trials Market Analysis
- 11.12 Australia Decentralised Clinical Trials Market Analysis
- 11.13 South Korea Decentralised Clinical Trials Market Analysis
- 11.14 Singapore Decentralised Clinical Trials Market Analysis
- 11.15 Taiwan Decentralised Clinical Trials Market Analysis
- 11.16 Rest of Asia Pacific Decentralised Clinical Trials Market Analysis
12 Latin America Decentralised Clinical Trials Market Analysis
- 12.1 Key Findings
- 12.2 Latin America Decentralised Clinical Trials Market Attractiveness Index
- 12.3 Latin America Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
- 12.4 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Country
- 12.5 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
- 12.6 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
- 12.7 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
- 12.8 Latin America Decentralised Clinical Trials Market Size Estimation and Forecast by Component
- 12.9 Brazil Decentralised Clinical Trials Market Analysis
- 12.10 Mexico Decentralised Clinical Trials Market Analysis
- 12.11 Argentina Decentralised Clinical Trials Market Analysis
- 12.12 Colombia Decentralised Clinical Trials Market Analysis
- 12.13 Rest of Latin America Decentralised Clinical Trials Market Analysis
13 MEA Decentralised Clinical Trials Market Analysis
- 13.1 Key Findings
- 13.2 MEA Decentralised Clinical Trials Market Attractiveness Index
- 13.3 MEA Decentralised Clinical Trials Market by Country, 2024, 2029 & 2034 (US$ Million)
- 13.4 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Country
- 13.5 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Study Design
- 13.6 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Indication
- 13.7 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by End-users
- 13.8 MEA Decentralised Clinical Trials Market Size Estimation and Forecast by Component
- 13.9 GCC Decentralised Clinical Trials Market Analysis
- 13.10 South Africa Decentralised Clinical Trials Market Analysis
- 13.11 Rest of MEA Decentralised Clinical Trials Market Analysis
14 Company Profiles
- 14.1 Competitive Landscape, 2023
- 14.2 Strategic Outlook
- 14.3 Castor
- 14.3.1 Company Snapshot
- 14.3.2 Company Overview
- 14.3.3 Product Benchmarking
- 14.3.4 Strategic Outlook
- 14.4 Clario
- 14.4.1 Company Snapshot
- 14.4.2 Company Overview
- 14.4.3 Product Benchmarking
- 14.4.4 Strategic Outlook
- 14.5 Clinical Ink
- 14.5.1 Company Snapshot
- 14.5.2 Company Overview
- 14.5.3 Product Benchmarking
- 14.5.4 Strategic Outlook
- 14.6 CLOUDZBYZ, Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Company Overview
- 14.6.3 Product Benchmarking
- 14.6.4 Strategic Outlook
- 14.7 Dassault Systemes SE (Medidata Solutions, Inc.)
- 14.7.1 Company Snapshot
- 14.7.2 Company Overview
- 14.7.3 Financial Analysis
- 14.7.3.1 Net Revenue, 2017-2023
- 14.7.3.2 R&D, 2017-2023
- 14.7.3.3 Regional Market Shares, 2023
- 14.7.4 Product Benchmarking
- 14.7.5 Strategic Outlook
- 14.8 Ergomed Group
- 14.8.1 Company Snapshot
- 14.8.2 Company Overview
- 14.8.3 Product Benchmarking
- 14.8.4 Strategic Outlook
- 14.9 Florence Healthcare, Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Company Overview
- 14.9.3 Product Benchmarking
- 14.9.4 Strategic Outlook
- 14.10 ICON Plc
- 14.10.1 Company Snapshot
- 14.10.2 Company Overview
- 14.10.3 Financial Analysis
- 14.10.3.1 Net Revenue, 2017-2023
- 14.10.3.2 Regional Market Shares, 2023
- 14.10.4 Product Benchmarking
- 14.10.5 Strategic Outlook
- 14.11 IQVIA Inc.
- 14.11.1 Company Snapshot
- 14.11.2 Company Overview
- 14.11.3 Financial Analysis
- 14.11.3.1 Net Revenue, 2017-2023
- 14.11.3.2 Regional Market Shares, 2022
- 14.11.4 Product Benchmarking
- 14.11.5 Strategic Outlook
- 14.12 KORE Wireless Group, Inc.
- 14.12.1 Company Snapshot
- 14.12.2 Company Overview
- 14.12.3 Financial Analysis
- 14.12.3.1 Net Revenue, 2019-2023
- 14.12.3.2 Regional Market Shares, 2023
- 14.12.4 Product Benchmarking
- 14.12.5 Strategic Outlook
- 14.13 Laboratory Corporation of America Holdings (Covance)
- 14.13.1 Company Snapshot
- 14.13.2 Company Overview
- 14.13.3 Financial Analysis
- 14.13.3.1 Net Revenue, 2017-2023
- 14.13.3.2 Regional Market Shares, 2022
- 14.13.4 Product Benchmarking
- 14.13.5 Strategic Outlook
- 14.14 Medable Inc.
- 14.14.1 Company Snapshot
- 14.14.2 Company Overview
- 14.14.3 Product Benchmarking
- 14.14.4 Strategic Outlook
- 14.15 Medrio
- 14.15.1 Company Snapshot
- 14.15.2 Company Overview
- 14.15.3 Product Benchmarking
- 14.16 Oracle Life Sciences
- 14.16.1 Company Snapshot
- 14.16.2 Company Overview
- 14.16.3 Financial Analysis
- 14.16.3.1 Net Revenue, 2017-2023
- 14.16.3.2 Regional Market Shares, 2022
- 14.16.4 Product Benchmarking
- 14.16.5 Strategic Outlook
- 14.17 Parexel International (MA) Corporation
- 14.17.1 Company Snapshot
- 14.17.2 Company Overview
- 14.17.3 Product Benchmarking
- 14.17.4 Strategic Outlook
- 14.18 ProPharma Group MIS Limited
- 14.18.1 Company Snapshot
- 14.18.2 Company Overview
- 14.18.3 Product Benchmarking
- 14.18.4 Strategic Outlook
- 14.19 Science 37
- 14.19.1 Company Snapshot
- 14.19.2 Company Overview
- 14.19.3 Product Benchmarking
- 14.19.4 Strategic Outlook
- 14.20 Signant Health (CRF Bracket)
- 14.20.1 Company Snapshot
- 14.20.2 Company Overview
- 14.20.3 Product Benchmarking
- 14.20.4 Strategic Outlook
- 14.21 Syneos Health
- 14.21.1 Company Snapshot
- 14.21.2 Company Overview
- 14.21.3 Financial Analysis
- 14.21.3.1 Net Revenue, 2017-2022
- 14.21.4 Product Benchmarking
- 14.21.5 Strategic Outlook
- 14.22 Thermo Fisher Scientific Inc. (PPD)
- 14.22.1 Company Snapshot
- 14.22.2 Company Overview
- 14.22.3 Financial Analysis
- 14.22.3.1 Net Revenue, 2017-2023
- 14.22.3.2 R&D, 2017-2023
- 14.22.3.3 Regional Market Shares, 2023
- 14.22.4 Product Benchmarking
- 14.22.5 Strategic Outlook
- 14.23 Veeva Systems
- 14.23.1 Company Snapshot
- 14.23.2 Company Overview
- 14.23.3 Financial Analysis
- 14.23.3.1 Net Revenue, 2017-2023
- 14.23.3.2 R&D, 2017-2023
- 14.23.3.3 Regional Market Shares, 2023
- 14.23.4 Product Benchmarking
- 14.23.5 Strategic Outlook
15 Conclusion and Recommendations
- 15.1 Concluding Remarks from Visiongain
- 15.2 Recommendations for Market Players